Gastric Cancer Foundation Founder, Joseph Peter Gallagher, Loses Battle With Stomach Cancer
03 avr. 2013 11h33 HE
|
Gastric Cancer Foundation
SAN CARLOS, CA--(Marketwired - Apr 3, 2013) - Joseph Peter (J.P.) Gallagher, passionate advocate of finding a cure for stomach cancer, passed away on February 26 after surviving stomach cancer for...
Sir Ken Robinson to Provide Keynote Address for Parents Education Network Education Revolution 2013 Event at AT&T Park
26 mars 2013 08h00 HE
|
Parents Education Network
SAN FRANCISCO, CA--(Marketwire - Mar 26, 2013) - Parents Education Network (PEN) today announced that Sir Ken Robinson, TED speaker, celebrated author and internationally recognized leader in the...
Virus Engineered to Express Melanin Offers New Possibilities to Diagnose and Treat Solid Tumor Cancers
11 févr. 2013 15h00 HE
|
Genelux
SAN DIEGO, CA--(Marketwire - Feb 11, 2013) - In a study released today in Proceedings of the National Academy of Sciences (PNAS), entitled "Vaccinia virus mediated melanin production allows MR and...
First Patient Treated in Genelux Phase I Trial With GL-ONC1 at Memorial Sloan Kettering Cancer Center
06 févr. 2013 08h34 HE
|
Genelux
SAN DIEGO, CA--(Marketwire - Feb 6, 2013) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based cancer therapies and companion diagnostics, today...
Genelux Corporation Announces Early Results of a Phase I/II Clinical Trial of Virotherapeutic GL-ONC1 in Advanced Peritoneal Cavity Cancers
01 nov. 2012 08h00 HE
|
Genelux Corporation
SAN DIEGO, CA--(Marketwire - Nov 1, 2012) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus based oncolytic cancer therapies and companion diagnostics,...
Genelux Corporation Announces Ground-Breaking Clinical Study Evaluating Oncolytic Vaccinia Virus in Canine Cancer Patients
28 juin 2012 11h00 HE
|
Genelux Corporation
SAN DIEGO, CA--(Marketwire - Jun 28, 2012) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based oncolytic (cancer-killing) therapies and companion...
Genelux Corporation Announces First Patient Dosed in Phase I Combination Clinical Trial of GL-ONC1
14 juin 2012 08h00 HE
|
Genelux
SAN DIEGO, CA--(Marketwire - Jun 14, 2012) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based oncolytic (cancer-killing) therapies and companion...
Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers
31 mai 2012 09h15 HE
|
Genelux
SAN DIEGO, CA--(Marketwire - May 31, 2012) - Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class,...
Genelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, Its Oncolytic Virus Lead Product Candidate
30 mai 2012 13h17 HE
|
Genelux
SAN DIEGO, CA--(Marketwire - May 30, 2012) - Genelux Corporation, a privately held, clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class,...